Trial Profile

A phase I/II trial of an oral mTOR protein kinase inhibitor (everolimus, RAD001) in combination with an oral EGFR tyrosine kinase inhibitor (erlotinib, Tarceva) in patients with metastatic breast cancer.

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 17 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

06 Apr 2011 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
06 Apr 2011 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
18 Oct 2010 Status changed from completed to discontinued as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com